Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
AssigneeUniversity of Virginia Patent Foundation
InventorsJohn C. HERR, Eusebio PIRES, Ryan D'SOUZA, Arabinda MANDAL, Kiley ANDERSON-KNAPP
Life of this patent
Estimating the term…
Abstract
The present disclosure provides anti-SAS1B antibodies, antigen-binding fragments thereof, and antibody-drug conjugates and methods of their use. This present disclosure also provides an isolated antibody or antigen-binding portion thereof having at least one of SB antibodies binding to surface exposed SAS1B, and 6B1 antibodies identifying at least one set of cancer patients testing positive for SAS1B expression.
Claims32
An isolated antibody or antigen-binding portion thereof comprising:
- a VH CDR1 of SEQ ID NO:1;
- a VH CDR2 of SEQ ID NO:2 or 6;
- a VH CDR3 of SEQ ID NO:3, 7, or 10;
- a VL CDR1 of SEQ ID NO:4, 8, or 11;
- a VL CDR2 of GAS or KVS;
- and a VL CDR3 of SEQ ID NO:5 or 9 or 95% Identity thereto.
An isolated antibody or antigen-binding portion thereof that specifically binds human SAS1B, wherein said antibody binds a same human SAS1B epitope recognized by a monoclonal antibody produced by a hybridoma cell line having ATCC number CRL-1581.
An isolated antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion specifically binds human SAS1B, wherein the antibody or antigen-binding portion thereof competes for binding with:
- an antibody or antigen-binding portion thereof having:
- a VH CDR1 of SEQ ID NO:1:
- a VH CDR2 of SEQ ID NO:2 or 6;
- a VH CDR3 of SEQ ID NO:3, 7, or 10;
- a VL CDR1 of SEQ ID NO:4, 8, or 11;
- a VL CDR2 of GAS or KVS;
- and a VL CDR3 of SEQ ID NO:5 or 9 or 95% identity thereto.
An isolated antibody or antigen-binding portion thereof, wherein said antibody or antigen-binding portion thereof inhibits binding of:
- an isolated antibody or antigen-binding portion thereof having a VH CDR1 of SEQ ID NO:1:
- a VH CDR2 of SEQ ID NO:2 or 6:
- a VH CDR3 of SEQ ID NO:3, 7, or 10;
- a VL CDR1 of SEQ ID NO:4, 8, or 11:
- a VL CDR2 of GAS or KVS;
- and a VL CDR3 of SEQ ID NO:5 or 9 or 95% identity thereto, to human SAS1B.
An isolated cell of hybridoma ATCC number CRL-1581.
An isolated polypeptide consisting of one of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or amino acids 24-163 of SEQ ID NO:26.
An isolated polynucleotide encoding an anti-human SAS1B antibody or antigen-binding portion thereof, wherein said isolated polynucleotide encodes a heavy chain and a light chain, wherein:
- an immunoglobulin heavy chain complementarity determining region (CDR) CDR1 includes SEQ ID NO:1, a CDR2 includes SEQ ID NO:2 or 6, and a CDR3 includes SEQ ID NO:3, 7, or 10, and wherein:
- an immunoglobulin light chain CDR1 includes SEQ ID NO:4, 8, or 11, a CDR2 includes GAS or KVS, and CDR3 comprise SEQ ID NO:5 or 9.
A method of detecting SAS1B-positive cells in a test sample, the method comprising:
- (a) determining a topology of an SAS1B molecule at SAS1B-positive cell surfaces by defining alternative splice variants that function as integral membrane proteins;
- and
- (b) mapping surface accessible epitopes recognized by an isolated antibody or antigen-binding portion thereof.
Dependencies are inferred from the claim text.